β-adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study
Article first published online: 20 DEC 2013
© 2013 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 77, Issue 1, pages 190–200, January 2014
How to Cite
Loth, D. W., Brusselle, G. G., Lahousse, L., Hofman, A., Leufkens, H. G. M. and Stricker, B. H. (2014), β-adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. British Journal of Clinical Pharmacology, 77: 190–200. doi: 10.1111/bcp.12181
- Issue published online: 20 DEC 2013
- Article first published online: 20 DEC 2013
- Accepted manuscript online: 17 JUN 2013 02:15AM EST
- Manuscript Accepted: 4 JUN 2013
- Manuscript Received: 3 SEP 2012
- Erasmus Medical Center and Erasmus University, Rotterdam
- Netherlands Organization for the Health Research and Development (ZonMw)
- Research Institute for Diseases in the Elderly (RIDE)
- Ministry of Education, Culture and Science
- Ministry for Health, Welfare and Sports
- European Commission (DG XII)
- Municipality of Rotterdam
- β-adrenoceptor blockers FEV1;
- FEV1 : FVC;
- population studies;
β-adrenoceptor blockers have been used with caution in patients with obstructive lung diseases such as asthma or chronic obstructive pulmonary disease (COPD), due to the potentially increased airway reactivity and risk of bronchial obstruction. Cardioselective β-adrenoceptor blockers have a more beneficial profile than non-cardioselective β-adrenoceptor blockers and can be safely prescribed to patients with both cardiovascular disease and COPD. We hypothesized that cardioselective β-adrenoceptor blockers also affect pulmonary function.
This study was performed within the Rotterdam Study, a prospective population-based cohort study. Effects of cardioselective and non-cardioselective β-adrenoceptor blockers on pulmonary function were analysed using regression techniques with multivariable adjustment for potential confounders.
Current use of non-cardioselective β-adrenoceptor blockers was significantly associated with a lower forced expiratory volume in 1 s (FEV1) of −198 ml (95% CI −301, −96), with a lower forced vital capacity (FVC) of −223 ml (95% CI −367, −79) and with a decreased FEV1 : FVC of −1.38% (95% CI −2.74, −0.13%). Current use of cardioselective β-adrenoceptor blockers was significantly associated with a lower FEV1 of −118 ml (95% CI −157, −78) and with a lower FVC of −167 ml (95% CI −222, −111), but did not affect FEV1 : FVC. After exclusion of patients with COPD, asthma and heart failure the effects of cardioselective β-adrenoceptor blockers remained significant for FEV1 (−142 ml [95% CI −189, −96]) and for FVC (−176 ml [95% CI −236, −117]).
In our study both non-cardioselective and cardioselective β-adrenoceptor blockers had a clinically relevant effect on both FEV1 and FVC. In contrast to cardioselective β-adrenoceptor blockers, use of non-cardioselective β-adrenoceptor blockers was associated with a significantly lower FEV1 : FVC.